Conflicts of Interest in United States Food and Drug Administration Advisory Committees: A Systematic Literature Review

Across 18 studies, financial conflicts of interest were common among FDA advisory committee participants, affecting 15% to over 70% of meetings for committee members and about one quarter of public speakers. While evidence linking member conflicts to committee voting outcomes was mixed, public speakers with financial conflicts were consistently 3 to 6 times more likely to provide testimony in favor of the approval of the drug under review.